Use of Short Oral Regimens for Treatment of Drug Resistant Tuberculosis in a Patient with HIV Infection
https://doi.org/10.58838/2075-1230-2023-101-1-68-73
Abstract
We present the clinical case of effective treatment of tuberculosis in a patient with disseminated pulmonary and extrapulmonary pre-extensive drug resistant tuberculosis, HIV-infection and other severe opportunistic and concomitant infections. Short all-oral regimen has been used for the treatment. This clinical case demonstrates the clinical efficacy of modern treatment regimens, good compatibility with other drugs and management of adverse events without treatment interruption.
About the Authors
S. Yu. Degtyareva
RUDN University
Russian Federation
Russian Federation
Svetlana Yu. Degtyareva, Assistant of Infectious Diseases Department with Training Courses in Epidemiology and Phthisiology, Medical Institute
6, Miklukho-Maklaya St., Moscow, 117198
Phone/Fax: +7 (495) 365-25-33
T. A. Kuznetsova
Vladimir Regional Center for Specialized Phthisiopulmonary Care
Russian Federation
Russian Federation
Tatiana A. Kuznetsova, Deputy Chief Physician for Medical Activities
63, Sudogodskoye Rd, Vladimir, 600023
Phone: +7 (492) 242-50-58
V. N. Zimina
RUDN University; National Medical Research Center of Phthisiopulmonology and Infectious Diseases
Russian Federation
Russian Federation
Vera N. Zimina, Doctor of Medical Sciences, Professor of Infectious Diseases Department with Training Courses in Epidemiology and Phthisiology, Medical Institute
6, Miklukho-Maklaya St., Moscow, 117198
Phone/Fax: +7 (495) 365-25-33
References
1. Klinicheskie rekomendatsii. Tuberkulez u vzroslykh. [Clinical guidelines on tuberculosis in adults.] ICD 10: A15-A19. Revised in 2022. Moscow, 2022, pp. 151. Available: https://cr.minzdrav.gov.ru/recomend/16_2
2. Federalnye klinicheskiye rekomendatsii po diagnostike i lecheniyu tuberkuleza organov dykhaniya s mnozhestvennoy i shirokoy lekarstennoy ustoichivostyu vozbuditelya. [Federal guidelines for diagnosis and treatment of respiratory tuberculosis with multiple and extensive drug resistance]. Rossiyskoe Obschestvo Ftiziatrov Publ., 72 p.
3. Filinyuk O.V., Schegertsov D.Yu., Kabanets N.N., Amichba D.E. Tolerability and Efficacy of Chemotherapy Containing Bedaquiline in Patients with Multiple Drug Resistant Pulmonary Tuberculosis. Tuberculosis and Lung Diseases, 2022, vol. 100 no. 9, pp. 40-45. (In Russ.) https://doi.org/10.21292/2075-1230-2022-100-9-40-45
4. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0; 2017. P. 155. Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm.
5. Global tuberculosis report 2017. Geneva: World Health Organization; 2017. P. 262. URL: https://reliefweb.int/sites/reliefweb.int/files/resources/9789241565516-eng.pdf.
6. Global tuberculosis report 2021. Geneva: World Health Organization; 2021. P. 43. URL: https://www.who.int/publications/i/item/9789240037021.
7. Ismail N. A., Omar S. V., Moultrie H. et al. Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study // Lancet Infect. Dis. – 2022. – Vol. 22 № 4. – P. 496-506. Available from: http://dx.doi.org/10.1016/S1473-3099(21)00470-9.
8. Lan Z., Ahmad N., Baghaei P. et al. Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis // Lancet Respir. Med. – 2020. – Vol. 8, № 4. – P. 383-394.
9. Meeting report of the WHO expert consultation on the definition of extensively drug-resistant tuberculosis. Geneva: World Health Organization; 2020. – P. 40. URL: https://www.who.int/publications/i/item/9789240018662.
10. Nasiri M. J., Zangiabadian M., Arabpour E. et al. Delamanid-containing regimens and multidrug-resistant tuberculosis: A systematic review and meta-analysis // Int. J. Infect Dis. – 2022. URL: https://doi.org/10.1016/j.ijid.2022.02.043.
11. von Groote-Bidlingmaier F., Patientia R., Sanchez E. et al. Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial // Lancet Respir. Med. – 2019. – Vol. 7, № 3. – P. 249-259.
12. WHO consolidated guidelines on tuberculosis. Module 4: treatmentdrug-resistant tuberculosis treatment. Geneva: World Health Organization; 2020. – Р. 146. URL: https://www.who.int/publications/i/item/9789240007048.
13. Wu S., Zhang Y., Sun F. et al. Adverse events associated with the treatment of multidrug-resistant tuberculosis: a systematic review and meta-analysis // Am. J. Ther. – 2016. - Vol. 23, № 2. - P. 521-530.
Review
For citations:
Degtyareva S.Yu., Kuznetsova T.A., Zimina V.N. Use of Short Oral Regimens for Treatment of Drug Resistant Tuberculosis in a Patient with HIV Infection. Tuberculosis and Lung Diseases. 2023;101(1):68-73. (In Russ.) https://doi.org/10.58838/2075-1230-2023-101-1-68-73
Views:
506
Email this article 